Genprex, Inc. (NASDAQ:GNPX) Sees Large Increase in Short Interest

Genprex, Inc. (NASDAQ:GNPX) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 634,600 shares, a growth of 46.5% from the November 30th total of 433,100 shares. Currently, 7.7% of the company’s stock are short sold. Based on an average daily volume of 9,290,000 shares, the short-interest ratio is presently 0.1 days.

Genprex Stock Down 4.1 %

Shares of NASDAQ:GNPX traded down $0.04 during trading on Monday, hitting $0.84. 174,040 shares of the company were exchanged, compared to its average volume of 2,560,859. Genprex has a fifty-two week low of $0.28 and a fifty-two week high of $14.40. The firm has a fifty day moving average price of $1.43 and a two-hundred day moving average price of $1.24.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Genprex stock. Armistice Capital LLC lifted its holdings in shares of Genprex, Inc. (NASDAQ:GNPX) by 122.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 218,000 shares of the company’s stock after buying an additional 120,132 shares during the period. Armistice Capital LLC owned about 10.39% of Genprex worth $411,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 14.05% of the company’s stock.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.